BLX 1.33KINS 0.24MCY 2.23DIS 2.56ATD.TO 1.43AXP 3.13TSM -9.74SNDK -203.92
Daily Stock Opinions and Ratings
Stockchase Opinions

David DriscollAptose BiosciencesAPS.TODON'T BUYJun 04, 2001

A hit and miss sector. Volatile.
David DriscollDavid Driscoll
Unknown
Unlock Rating
$1.60

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

PARTIAL BUY

Aptose Biosciences(APS.TO)

Jul 05, 2019
Don't get scared of parabolic moves. The chart looks very good. It has shot up in the last 6 weeks. Its next move could be just under $6 pretty quickly. Relative strength vs. the S&P looks very good. However, expect volatility. Own a small holding.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSIUnlock Rating
$3.93

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
RISKY

Aptose Biosciences(APS.TO)

Apr 21, 2014

An old story, but re-invigorated by an impressive management team. Speculative. Recent sell off in biotech has not helped them.

Photo of Fabrice TaylorFabrice TaylorUnlock Rating
$0.54

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
SELL

Aptose Biosciences(APS.TO)

Nov 17, 2005
At this point, it's a lottery ticket, so for a conservative, fundamental investor, he would call it a sell. Their therapy for pancreatic cancer hasn't been shown to be effective. Be very, very cautious over the next couple of months because it's an orphan stock and you are going into tax loss selling.
Photo of Peter HodsonPeter HodsonUnlock Rating
$0.29

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Aptose Biosciences(APS.TO)

Sep 29, 2005
A very interesting company. Has always been a bit of a disappointment. Once they get their FDA approval then the stock should go.
Photo of Robert FloydRobert Floyd
Owned
Unlock Rating
$0.67

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Aptose Biosciences(APS.TO)

Jun 28, 2004
One of the more undervalued of the biotech's. Have a number of interesting products that are being developed. Has been disappointed in the stock performance. Need some news that will push the valuation.
Photo of Robert FloydRobert Floyd
Owned
Unlock Rating
$0.84

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Aptose Biosciences(APS.TO)

Jun 01, 2004
Have done well getting approvals on their products but the stock hasn't done very much. Would like to get rid of his holdings, but not at this price.
Photo of Robert FloydRobert Floyd
Owned
Unlock Rating
$0.86

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Aptose Biosciences(APS.TO)

Apr 19, 2004
Not their favorite biotech. Cancer Institute has given them a lot of money for phase two studies. Possibly have a very elegant solution. Expect there will be a lot of news as phase two trials proceed. Volatile. Early stages so only buy a little.
Photo of Hugh McCauleyHugh McCauley
Owned
Unlock Rating
$1.06

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Aptose Biosciences(APS.TO)

Dec 09, 2003
Highly speculative. A very high number of shares outstanding. Trading below its 50/200 day moving average. Struggling to hold on to its current level. Have had 10 quarters of losses.
Photo of Lou SchizasLou SchizasUnlock Rating
$1.04

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Aptose Biosciences(APS.TO)

Dec 08, 2003
A very interesting stock at this price. Good cancer drugs. Still awaiting trial completions in the US. Also have new products.
Photo of Robert FloydRobert Floyd
Owned
Unlock Rating
$1.07

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Aptose Biosciences(APS.TO)

Sep 22, 2003
Getting a lot of patent approvals. A growth story in the making. Have an extensive profile. Have recently flushed out their balance sheets with an issue. A very interesting story, but can be somewhat volatile.
Photo of Robert FloydRobert Floyd
Owned
Unlock Rating
$1.29

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Aptose Biosciences(APS.TO)

Aug 20, 2003
High-risk company.You should own five or six in this sector in order to spread the risks.
Photo of Mark Jackson, CFAMark Jackson, CFA
No
Unlock Rating
$1.23

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Aptose Biosciences(APS.TO)

Jul 21, 2003
Charts indicate a risky stock. If you want to buy, pick a point 10/15% below its recent low.
Photo of Larry Berman CFA, CMT, CTALarry Berman CFA, CMT, CTA
No
Unlock Rating
$1.18

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Aptose Biosciences(APS.TO)

Jul 04, 2003
Just did a financing to extend development on new products. Sees further improvement.
Photo of Robert FloydRobert Floyd
Owned
Unlock Rating
$1.25

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Aptose Biosciences(APS.TO)

Jun 24, 2003
Has never generated any degree of profitability. Speculative.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
No
Unlock Rating
$1.23

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Aptose Biosciences(APS.TO)

May 14, 2003
Received patent approval on one of their processes. New drugs for cancer are being tested in Mexico and USA. You have to keep an eye on this one.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$1.41

Stock price when the opinion was issued

$2.40

As of Jul 03, 2026. Market Open.

biotechnologypharmaceutical

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NRIM 0$
MAL.TO -0.56$31.78
HUZ.TO -0.94$22.6
CNR.TO 5.9$180.16
CP.TO 3.37$130.46

Today's Top Picks

BLX 1.33$59.94
KINS 0.24$19.75
MCY 2.23$107.49
DIS 2.56$99.71
ATD.TO 1.43$90.41

Popular Articles

Latest Sell Signals

DOL.TO 2.98$188.95
LULU 1.37$118.79
GIB.A.TO 3.12$95.7
BB.TO -2.13$12.84
MU -51.08$853.2

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Martin Cobb, ASIP

Martin Cobb, ASIP

Lorne Steinberg Wealth Management

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Colin Cieszynski

Colin Cieszynski

SIA Wealth Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically